ADVANCED THERAPIES WEEK
Powered by PHACILITATE

Tozaro & Smart Polymer™ Platform

11th February 2026

Jason H Slingsby
CEO

tozaro

Pharma committed, Blockbusters & Strong Pipeline

C&GT is the Future: A “Cure” is better than treatment



22

2/3 Top Pharma investing

Two CGT blockbusters from 2021-2024	zolgensma, YESCARTA
Two more blockbusters in 2025	CARVYKTI, Breyanzi
This year’s newcomers are fueled by explosive YoY growth	111% YoY (9 months ended September 2025); 101% YoY (9 months ended September 2025)
Current blockbusters poised to become multi-billion dollar products	zolgensma, itvisma, CARVYKTI, Breyanzi — Consensus revenue forecasts show these blockbusters are poised to reach $2B in revenue between 2026 and 2031
~6 more blockbusters are expected by 2031	~10 total blockbusters expected by 2031, according to analyst consensus data

Increasing # Blockbusters



Growing Pipeline:
Rare AND common diseases
In vivo CAR-T promise

tozaro

Transformative but expensive – Industrialisation Challenges

Cell & Gene Therapy: The “Catch”



Very high cost per treatment

$1.5m+ per vv batch

Batch yields only ca. **30%**

tozaro

Incremental Innovation and limited uptake of biologics

Current DSP Technology & Competition

Simple



Traditional Chromatography

Selection of +/- charged compounds (AEX)
Selection on basis of size (SEC)
Mixed mode chromatography

- Cost-effective
- Stable
- Not specific/selective to target
- Multiple orthogonal steps required

Intermediate



Unexplored chemical space

Intermediate complexity between small molecules & biologics while achieving specific/selective binding

- Cost-effective
- Stable
- Specific/selective to target
- Fewer purification steps required

Complex



Peptide/mAb affinity ligands

Selection by binding specific protein epitopes
Peptides have secondary structure
mAb have secondary & tertiary structure

- Less cost-effective
- Less stable
- Specific/selective to target
- Fewer purification steps required

tozaro

Polymers which bind targets specifically & selectively

Solution: Smart Polymer™ Platform



Vast new chemical space vs. mAbs/peptides



In silico/ML guided discovery platform (1 mo.)

Smart Polymer™ Affinity Ligands

- Monomers achieve **specific & selective** binding to target
- Fully chemical synthesis complete in 2 days
- **Cost effective** & scalable manufacture
- **Stability advantages** of polymers vs. biologics
- Chemical immobilization options onto solid supports

tozaro

Technical Proof of Concept

Tozaro Products: Lenti & panAAV Purification



VSVG-LV-LP001 Run Results	
Loading Flowrate	5 BV/min
Membrane Capacity	4.7 E11 VP/mL
Total Bound Lentivirus Recovery	50%
Functional Bound Lentivirus Recovery	43%
Total Protein Reduction	99.8%
Total DNA Reduction	99.9%

1 VSV-G/lentivirus Ligands

- LP candidate immobilized on membrane
- High recoveries of functional LV (specificity)
- V low HCP & DNA (selectivity)
- Working on other solid supports too

- **First-in-class** potential in GMP settings



2 panAAV serotype ligands

- LPs designed against 13 AAV serotypes
- Screened for bind/elute to AAV1,2,5,9
- Multiple LPs identified
- Working on resin/bead supports & others

- **Best-in-class** potential in existing AAV market

SARTORIUS

LVF1-012-B			
LV Titre			
[Known] (TU/mL)	[Calc.] (TU/mL)	Acc. (%)	CV (%)
1.73×10^8	1.70×10^8	-1.73	5.6
8.65×10^7	9.13×10^7	+5.55	3.5
4.33×10^7	4.29×10^7	-0.92	5.0
2.16×10^7	2.01×10^7	-6.94	2.8
1.08×10^7	9.02×10^6	-16.48	9.7
5.41×10^6	5.04×10^6	-6.84	7.1
2.70×10^6	3.49×10^6	+29.26	12.3



3 Rapid Analytics (<2min)

- Smart Polymers on BLI sensor (Octet/Sartorius)
- Quantitative measurement of LV & panAAV in <2min
- Alternative to ELISAs (>6 hours)
- In-line analytics to inform GMP decisions

tozaro

Market: Smart Polymer™ Platform Applications

Bottleneck

Recovery	Strain changes	Economics	Recovery	Purity	Purity	Purity
Viral Vectors Lenti, AAV  **$600m market**	**Viral Vaccines** Seasonal, Pandemic  **>$1bn market**	**mAbs** Protein A binding  **$1.5bn market**	**Novel mAbs**  **$ growing mkt**	**DNA/ RNA** Various  **$ growing mkt**	**Proteins** Various  **$ large market**	**Cells** T, Stem, NK etc.  **$ bn market**
Recovery, Purity	Rapid ligand design	Cost Advantage	Selectivity	Selectivity	Selectivity	Selectivity

USP

Smart Polymer™ Platform – *in silico*/ML driven – 509 letter alphabet

tozaro

Smart Polymer™ Platform Commercialisation

Tozaro Business Model

tozaro Business Model

R&D funding & Tech Access

Revenue share on Product Sales utilizing Smart Polymers™

Affinity Target Nomination → *In silico* & ML design → Ligand Discovery Chemistry (BLI) → Candidate Panel nomination (Beads) → Solid support Optimisation → Application PoC → Economic modelling & real world evidence → Product Commercialisation

tozaro → Ligand Supply: R&D, and ISO-certified (margin-based)

Chromatography Companies

ThermoFisher SCIENTIFIC, cytiva, REPLIGEN, SARTORIUS, MilliporeSigma, ECOLAB, BIO-RAD, Biotage, AsahiKASEI

Monolith

Membrane

Bead/Resin

tozaro

Upcoming Milestones for 2026

- New funding round to accelerate progress into mid 2027
- Product development partnerships with leading chromatography companies
- Launch of research use only (RUO) LV product to accelerate revenue growth
- Announce data from first Smart Polymer™ biologics program
- Initiating new Smart Polymer™ platform projects with Partners

Questions ?

Tozaro Ltd.

The Exchange
Colworth Park, Bedford, MK44 1LQ, UK

www.Tozaro.com

Jason.Slingsby@tozaro.com

+44 (0)7353 101344